HUTCHMED (China) Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HUTCHMED (China) Limited - overview
Established
2002
Location
Hong Kong, -, Hong Kong SAR - China
Primary Industry
Pharmaceuticals
About
Established in 2002 and based in Kowloon, Hong Kong, HUTCHMED (China) Limited, f. k. a Hutchison China MediTech Limited, d. b.
a. HUTCHMED develops, manufactures, and distributes prescription drugs as well as consumer health products. It focuses on therapeutics and immunotherapies for the treatment of cancer and autoimmune diseases, as well as Chinese traditional medicine. In April 2021, Baring Private Equity Asia agreed to invest USD 100 million in HUTCHMED (China) Limited to acquire 16.
393 million shares at USD 30. 5 per share. Furthermore, in June 2021, Carlyle Group acquired a minority stake in HUTCHMED (China) Limited. for approximately USD 210 million, and the company also raised HKD 4.
17 billion in an IPO, selling 104. 0 million shares at HKD 40. 10 per share on the Hong Kong stock exchange. The company is focused on commercial-stage biopharmaceuticals that is committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
The company currently has advanced ten cancer drug candidates into clinical studies across the world. The company generates revenue through the manufacture and distribution of prescription drugs and consumer health products. The growth plans of the company include a strategy to accelerate its oncology revenues from its Elunate, Silanda, and the potential upcoming approval of savolitinib.
Current Investors
General Atlantic, EQT, Carlyle Group
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Alternative Medicine, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.hutch-med.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
HUTCHMED (China) Limited - timeline of key events
HUTCHMED (China) Limited - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 195,392,000 | 45,970,000 | 91,813,000 | 178,203,000 | 216,080,000 | 241,203,000 | 214,109,000 | 204,890,000 | 227,976,000 | 356,128,000 | - | - | - |
| % Revenue Growth (YoY) | - | (76.5%) | 99.7% | 94.1% | 21.3% | 11.6% | (11.2%) | (4.3%) | 11.3% | 56.2% | - | - | - |
| EBITDA (USD) | 16,160,000 | 12,518,000 | 9,365,000 | (7,756,000) | (44,264,000) | (50,692,000) | (88,975,000) | (141,249,000) | (190,564,000) | (321,083,000) | - | - | - |
| Operating Income (USD) | 12,111,000 | 11,555,000 | 8,100,000 | (9,771,000) | (46,697,000) | (53,417,000) | (92,641,000) | (146,386,000) | (196,668,000) | (328,317,000) | - | - | - |
| Operating Margin | 6.2% | 25.1% | 8.8% | (5.5%) | (21.6%) | (22.1%) | (43.3%) | (71.4%) | (86.3%) | (92.2%) | - | - | - |
| % EBITDA Margin | 8.3% | 27.2% | 10.2% | (4.4%) | (20.5%) | (21.0%) | (41.6%) | (68.9%) | (83.6%) | (90.2%) | - | - | - |
| NET Income (USD) | 3,540,000 | 7,042,000 | 7,275,000 | 10,427,000 | 14,557,000 | (22,963,000) | (71,286,000) | (103,679,000) | (115,517,000) | (167,041,000) | - | - | - |
| % Net Margin | 1.8% | 15.3% | 7.9% | 5.9% | 6.7% | (9.5%) | (33.3%) | (50.6%) | (50.7%) | (46.9%) | - | - | - |
HUTCHMED (China) Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Hutchison Pharmaceuticals | - | ||||||||
| IPO | Completed | HUTCHMED (China) Limited | - | ||||||||
| PIPE | Completed | HUTCHMED (China) Limited | - | ||||||||
| PIPE | Completed | HUTCHMED (China) Limited | - | ||||||||
| PIPE | Completed | HUTCHMED (China) Limited | - |
Displaying 1 - 5 of 5
HUTCHMED (China) Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.